Donepezil for mild cognitive impairment in Parkinson’s disease

We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-02, Vol.11 (1), p.4734-4734, Article 4734
Main Authors: Baik, Kyoungwon, Kim, Seon Myeong, Jung, Jin Ho, Lee, Yang Hyun, Chung, Seok Jong, Yoo, Han Soo, Ye, Byoung Seok, Lee, Phil Hyu, Sohn, Young H., Kang, Seung Wan, Kang, Suk Yun
Format: Article
Language:English
Subjects:
692/617/375
692/617/375/346/1718
Cognitive ability
Dementia
Dementia disorders
Donepezil
EEG
Electroencephalography
Humanities and Social Sciences
Movement disorders
multidisciplinary
Neurodegenerative diseases
Parkinson's disease
Patients
Science
Science (multidisciplinary)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group. The treatment group received donepezil for 48 weeks. The primary outcome measures were the Korean version of Mini-Mental State Exam and Montreal Cognitive Assessment scores. Secondary outcome measures were the Clinical Dementia Rating, Unified Parkinson’s Disease Rating Scale part III, Clinical Global Impression scores. Progression of dementia was assessed at 48-week. Comprehensive neuropsychological tests and electroencephalography (EEG) were performed at baseline and after 48 weeks. The spectral power ratio of the theta to beta2 band (TB2R) in the electroencephalogram was analyzed. There was no significant difference in the primary and secondary outcome measures between the two groups. However, the treatment group showed a significant decrease in TB2R at bilateral frontotemporoparietal channels compared to the control group. Although we could not demonstrate improvements in the cognitive functions, donepezil treatment had a modulatory effect on the EEG in PD-MCI patients. EEG might be a sensitive biomarker for detecting changes in PD-MCI after donepezil treatment.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-84243-4